recently reported the analysis of PTEN and PIK3CA expression in samples from patients with recurrent or metastatic HNSCC enrolled in two trials of cetuximab-based therapy (n=48 patients in the E5397 trial and n=37 in the NCI-8070 trial) (117). The gene discussed is PTEN; the disease is head and neck squamous cell carcinoma.